Sanofi (SNY) Sees Unusually-High Trading Volume
Sanofi (NYSE:SNY) shares saw unusually-high trading volume on Monday . Approximately 1,742,644 shares changed hands during mid-day trading, an increase of 19% from the previous session’s volume of 1,464,283 shares.The stock last traded at $39.44 and had previously closed at $39.67.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Berenberg Bank reiterated a “hold” rating and issued a $93.00 target price on shares of Sanofi in a research report on Monday, August 15th. Barclays PLC upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating in a research report on Thursday, May 12th. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Sanofi in a research report on Monday, April 25th. Finally, Citigroup Inc. reiterated a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and an average target price of $60.50.
The company’s 50 day moving average price is $41.14 and its 200-day moving average price is $40.70. The stock has a market capitalization of $101.42 billion and a P/E ratio of 21.95.
Other hedge funds and institutional investors recently modified their holdings of the company. BlackRock Advisors LLC boosted its position in shares of Sanofi by 115.1% in the fourth quarter. BlackRock Advisors LLC now owns 695,109 shares of the company’s stock worth $29,646,000 after buying an additional 372,000 shares during the last quarter. Stephens Inc. AR boosted its position in Sanofi by 4.5% in the fourth quarter. Stephens Inc. AR now owns 56,811 shares of the company’s stock worth $2,423,000 after buying an additional 2,424 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Sanofi by 7.3% in the fourth quarter. Rhumbline Advisers now owns 26,510 shares of the company’s stock worth $1,131,000 after buying an additional 1,800 shares in the last quarter.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.